Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences
January 04 2021 - 7:30AM
Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in
innovative pharmaceutically-produced transdermal cannabinoid
therapies for rare and near-rare neuropsychiatric disorders, today
announced that Armando Anido, Chief Executive Officer of Zynerba,
will participate in two upcoming virtual investor conferences. Mr.
Anido will participate in a fireside chat during the
H.C.
Wainwright BioConnect Conference which will be available
on demand January 11-14, 2021. He will also present a company
overview during the
ICR Conference 2021 on
Thursday, January 14, 2021 at 10:00 a.m. ET.
Investors interested in arranging a virtual meeting with the
Company’s management during the ICR Conference 2021 should contact
the conference coordinator or brandon.weiner@westwicke.com.
Webcasts of both conferences will be accessible under the Events
& Webcasts tab of the Investor section of Zynerba’s website at
www.zynerba.com.
About Zynerba Pharmaceuticals, Inc. Zynerba
Pharmaceuticals is the leader in pharmaceutically-produced
transdermal cannabinoid therapies for rare and near-rare
neuropsychiatric disorders. We are committed to improving the lives
of patients and their families living with severe, chronic health
conditions including Fragile X syndrome, autism spectrum disorder,
22q11.2 deletion syndrome, and a heterogeneous group of rare and
ultra-rare epilepsies known as developmental and epileptic
encephalopathies. Learn more at www.zynerba.com and follow us on
Twitter at @ZynerbaPharma.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should” or other words that convey uncertainty of
future events or outcomes to identify these forward-looking
statements. Such statements are subject to numerous important
factors, risks and uncertainties that may cause actual events or
results to differ materially from the Company’s current
expectations. These and other risks are described in the Company’s
periodic reports, including the annual report on Form 10-K,
quarterly reports on Form 10-Q and current reports on Form 8-K,
filed with or furnished to the Securities and Exchange Commission
and available at www.sec.gov. Any forward-looking statements
that the Company makes in this press release speak only as of the
date of this press release. The Company assumes no obligation to
update forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Investor ContactPeter VozzoWestwicke, an ICR
Company Office: 443-213-0505Cell:
443-377-4767peter.vozzo@westwicke.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Sep 2023 to Sep 2024